Drug Type Gene therapy |
Synonyms HER2-t-haNK -ImmunityBio |
Target- |
Action- |
Mechanism Immunologic cytotoxicity, Natural killer cell replacements |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Glioblastoma | Phase 1 | United States | 27 Jul 2022 |